



#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Hanna et al.

Group Art Unit: 1644

Application Serial No. 09/855,717

Examiner: P. Gambel

Filed: May 16, 2001

Title: Treatment of B-Cell Malignancies Using Combination of B Cell Depleting Antibody and Immune Modulating Antibody Related Applications

* * * * *

ELECTION RESPONSE

Hon. Commissioner of Patents
Washington, D.C. 20231

RECEIVED

MAR 13 2003

Sir:

In response to the Office Action mailed February 11, 2003, Applicants elect with TECH CENTER 1600/2900 traverse Group B, directed in a CD40L-specific antibody and a second antibody (e.g. a CD20-specific antibody). As to the species Applicants elect, as to radiolabel yttrium 90, and as to the chemotherapeutic CHOP. Finally, as to disease Applicants elect B cell lymphoma and Non-Hodgkin's disease.

The traverse is on the basis that the search required for the different methods is highly related as an involve treatment of B cell malignancies using a CD40L specific antibody alone or in combination with other therapeutic agents.

If the Examiner has any questions relating to this response or any other matter he is respectfully requested to contact the undersigned.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Robin L. Teskin

Robin L. Teskin

Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Election

U.S. Serial No. 09/855,717

Atty Reference: 037003-080623

Page 2

Date: March 11, 2003

Attorney Reference: 037003-0280623

/rg